PharmaVentures has become the latest Partner to join forces with One Nucleus. Both PharmaVentures and One Nucleus are committed to playing an active and supportive role in assisting in the success of the life sciences sector nationally and internationally. 

OXFORD, UK, October 1st, 2014 PharmaVentures is pleased to announce that it has acted as advisor on deal terms to Plethora Solutions Holdings on their recently signed Licensing Agreement with Recordati to commercialise PSD502™, a novel treatment for premature...

OXFORD, UK, September 24th, 2014 PharmaVentures are delighted to announce that Aki von Roy has joined as an Associate, based in Auckland, New Zealand. He has over 30 years experience in Big Pharma and 16 years in biotech. Aki has been involved in over 18 start-up or...

PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis’ unique therapeutic approach, which will be used in the clinical development of potential…

PharmaVentures is pleased to announce the appointment of Dr Christopher Berry, formerly of Sanofi’s R&D Transactions Group, as an Associate in the corporate advisory team. Based in Paris, France, Dr Berry has negotiated 56 signed deals since 2010…

PharmaVentures is pleased to announce that it acted as exclusive advisor on the sale of Medical Insight, the Danish enterprise imaging software company, to Karos Health, based in Ontario, Canada. The sale was completed in June…

PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May,…

PharmaVentures is pleased to announce the appointment of Latin American expert Valeria Uribe as associate to significantly enhance the global reach of the Corporate Advisory team. A dynamic professional with formal education in…

PharmaVentures is pleased to announce that it has been engaged by Tiziana Life Sciences, Plc. to provide independent valuation advice for assets acquired as part of it’s successful admission onto London Stock Exchange’s AIM in April 2014.
Tiziana Life Sciences, is a London…

PharmaVentures is pleased to announce that it has been appointed by Novartis as advisors on the future options for its UK Horsham site. These options could include reusing part of the site as a science or business park, thereby creating a legacy with the possibility…

PharmaVentures is pleased to announce the appointment of expert industry executive Nigel Trim as an associate to significantly enhance PharmaVentures Corporate Advisory offering to the CRO space. 
Over the last 30 years, Nigel has worked…

PharmaVentures is pleased to announce that it has acted as exclusive M&A advisor to NanoSight in the successful sale of the company to Malvern Instruments, a Spectris plc company. Malvern completed the acquisition on 30th September 2013.

PharmaVentures is pleased to announce that Techno Group Investment Holdings, a portfolio company of Gulf Capital, has acquired 100% of Doğu Tip, a Turkish provider of outsourced diagnostic imaging services, with a subsequent allocation of 25% incentive…

PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi’s divestment of its Zentiva subsidiary’s production plant in Hlohovec, Slovakia.

Oxford, UK, October 18th,  2012 PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing PharmaVentures’ corporate finance capabilities and offerings to the global healthcare...

Oxford, UK, March 21st, 2012 Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments...

Oxford, UK, March 19th, 2012 The pharmaceutical and biotechnology industry is undergoing considerable change as the patent cliff looms, fostering invention and change, and a strong need for successful partnering. There are also new opportunities to develop in emerging...

Oxford, UK, January 12th,  2012 - PharmaVentures announced today that it was delighted to play an advisory role in the Sanofi – Covance deal which won Scrip’s ‘Outsourcing Deal of the Year 2011’. The judges described the deal as ‘impressive’ as it was “one...